Keiji AI LogoKeiji AI
For Diagnostics & Data Platforms

Ship the analytics layer your biopharma customers are asking for

Your data asset is valuable but comparable data is available elsewhere. Your customers want feasibility, cohort extraction, and outcome analysis — not raw access. TrialMind embeds by API or MCP, white-label or co-branded, deployed in the customer's environment, in weeks.

What Platform Teams Get

The product layer, without the product organisation

Ships as your product

Your biopharma customers increasingly want feasibility, cohort extraction, and outcome analysis rather than raw data access. TrialMind embeds by API or MCP, white-label or co-branded, so the capability arrives under your brand rather than as an obvious third-party dependency.

REST API and MCP server access
White-label or co-branded, your choice
Fits your product roadmap rather than ours
Your customer relationship stays yours

Weeks, not a product organisation

Building this yourself means standing up a clinical analytics product organisation you do not have and do not want. The agents and tool infrastructure already exist, so embedding is measured in weeks and does not start with hiring a clinical domain team.

Production agent infrastructure already built
100+ clinical MCP tools available from day one
No clinical domain team to recruit first
Differentiates a data asset that is otherwise comparable elsewhere

Deploys where the data already is

The first objection your biopharma customers raise is where their data goes. TrialMind deploys into the customer's own environment with raw data never leaving it — answered architecturally, so you are not negotiating it deal by deal.

Runs inside the customer's environment
Raw records never leave their control
Audit trails on every analysis, because outputs reach submissions
Security posture you can put in front of their review board
Deployment & Governance

Answers the objection your customers raise first

Data partnerships stall on where the data goes and whether the analysis can be defended. Both are properties of the architecture here.

Raw data never moves

Deployment into the customer's environment is the default. This is the objection that stops data partnerships, and it is answered in the architecture rather than in a contract clause.

Audit trails end to end

Your customers take these outputs into regulatory submissions, so every analysis carries traceable, reproducible provenance.

Built to your roadmap

We are small enough to build against your product plan rather than asking you to wait for ours.

FAQ

Frequently Asked Questions

How does the integration actually work?

Two paths. A REST API for conventional product integration, and an MCP server if you want the agents callable as tools from your own assistant or workflow layer. Most partners start with the API and add MCP once they know which workflows their customers use most.

Can we white-label it?

Yes. White-label or co-branded, whichever fits your positioning. The point is that it ships as your product rather than as a visible third-party dependency inside it.

Where does our customers' data go?

Nowhere. TrialMind deploys into the customer's own environment and raw records never leave it. This is usually the first question your biopharma customers ask, and it is answered by the deployment model rather than by a data processing agreement.

How long does an embed take?

Weeks rather than years, because the agents and tool infrastructure already exist. What varies is the depth of integration with your platform, not the time to build clinical analytics capability from scratch.

Who owns the customer relationship?

You do. We are the layer inside your product, and we attribute any biopharma customer onboarded through it. We are explicit about this at the start so that neither side is guessing later.

What if we later build this ourselves?

That is a reasonable thing for you to consider, and we would rather structure the agreement knowing it than pretend otherwise. What we ask for is a clear commercial framework across the workstreams rather than one negotiated in isolation.